- Home
- SLN vs LPAA Comparison
SLN vs LPAA Comparison
Compare SLN & LPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLN | LPAA |
|---|---|---|
| Founded | 1994 | 2024 |
| Country | United Kingdom | United States |
| Employees | 88 | 2 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.9M | 310.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLN | LPAA |
|---|---|---|
| Price | $6.70 | $10.81 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $42.60 | N/A |
| AVG Volume (30 Days) | ★ 173.6K | 31.1K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.19 | $10.39 |
| 52 Week High | $8.40 | $10.83 |
Technical Indicators
Market Signals| Indicator | SLN | LPAA |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 65.53 |
| Support Level | $5.76 | $10.40 |
| Resistance Level | $7.48 | N/A |
| Average True Range (ATR) | 0.57 | 0.01 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 64.41 | 87.50 |
Price Performance
Historical ComparisonAbout SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.